Etamsylate is a haemostatic agent that is used for the management of blood loss. Apparently etamsylate increases capillary wall resistance and platelet adhesives by inhibition of the biosynthesis of prostaglandins causing platelet disaggregation in a presence of vascular wound. Recent studies suggest that etamsylate antagonizes anti-coagulant activity of heparin.
It is used for the management of blood loss; inhibits of the biosynthesis of prostaglandins causing platelet disaggregation
Caution
Hygroscopic
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
In this retrospective study we aimed to compare the effect of tranexamic acid (TXA) vs etamsylate, two hemostatic agents, on hematuria duration in autosomal dominant polycystic kidney disease (ADPKD) patients with persistent gross hematuria. This is a retrospective study of
European journal of pharmacology, 827, 167-172 (2018-03-21)
Etamsylate is indicated for several anti-hemorrhagic indications in human and veterinary medicine. However, etamsylate has been shown to be effective only in specific hemorrhagic situations. Furthermore, mechanism of action of etamsylate is not known but recent research has shown its
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
